RecruitingNot ApplicableNCT07220369

Gut Mini-Pill Study

Evaluation of Ingestible Mini-pill for Gastrointestinal Regional Luminal Content Sampling


Sponsor

Tufts University

Enrollment

30 participants

Start Date

Sep 8, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this proof-of-concept study in humans is to determine if a noninvasive, ingestible device, called a "mini-pill", can collect gastrointestinal (GI) luminal content samples from 2 different locations along the GI tract after consumption of diets differing in protein source (meat and plant-based meat alternatives). The mini-pills will be recovered in the stool. We will analyze the microbial profile of the mini-pill contents and in stool, and also measure blood biomarkers related to cardiometabolic risk, to better understand the relationship between diet, microbiota and health.


Eligibility

Min Age: 50 YearsMax Age: 75 Years

Inclusion Criteria10

  • Men and postmenopausal women
  • Age >50 to <75 years
  • BMI >20 to <35 kg/m2
  • Normotensive with or without medication
  • Normal gastrointestinal function with regular bowel movements at least once every other day
  • Normal kidney and liver function
  • Willingness to swallow the mini-pills
  • Willingness to collect and return multiple stool samples
  • Adequate refrigerator and freezer space to store study entrées
  • Intent to remain in the greater Boston area during the intervention periods

Exclusion Criteria21

  • Individuals self-reporting adhering to any type of vegetarian diet
  • Lack of willingness to restrict fish intake to less than once per week during the dietary intervention phases
  • Allergy/intolerance/religious reasons to avoid study foods or food ingredients, including known hypersensitivity to Blue 1 food coloring and wheat gluten.
  • Regular use of prebiotics or probiotics within the past 3 months
  • Regular use of laxatives or fiber supplements
  • Chronic constipation
  • Chronic use of antibiotics (except topical)
  • Regular use of stomach acid lowering and weight loss medications such as GLP-1 agonists
  • Use of dental prophylaxis
  • Planned colonoscopy 2 months prior to or during the study period
  • Gastroparesis
  • Swallowing disorder, or inability or difficulty taking pills
  • Malabsorptive and inflammatory bowel disease, diverticulosis, and history of diverticulitis, gastric/ esophageal/intestinal surgery, including lap banding or bariatric surgery.
  • History of bowel obstruction, pancreas and liver disorders.
  • Any form of active substance abuse or dependence (including drug or alcohol abuse). This information will be stored in REDCAP in a subsection that has no identifiers.
  • Established major chronic diseases such as cardiovascular disease, diabetes, active cancer within the last 5 years, or any significant medical condition at the study MD's discretion
  • A clinical condition that, in the judgment of the study MD or principal investigator, could potentially pose a health risk to the subject while involved in the study.
  • Unwillingness to adhere to study protocol
  • Intent to increase or decrease body weight during the study period
  • No Social Security number (for payment and IRS forms).
  • Individuals who directly report to any member of the research team.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERplant-based meat alternative entrees

2 plant-based meat alternatives per day

DEVICEmini-pill

mini-pills which sample at different locations in the gut

OTHERmeat based entree

2 meat based entrees per day


Locations(1)

Jean Mayer Human Nutrition Research Center on Aging

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07220369


Related Trials